Oncternal Therapeutics, Inc. (ONCT) Comparison with companies in other sectors?

Oncternal Therapeutics, Inc. has a share price of 2.96M. You can analyze Oncternal Therapeutics, Inc. (ONCT) competitors across different market sectors through stock heatmaps.

What are ONCT's NET and operating margins?

Oncternal Therapeutics, Inc. (ONCT) operating margin is around -21.57, and net profit margin is approximately -20.74 as of the latest reports.

In what way does ONCT's earnings per share (EPS) trend reflect its financial momentum?

Oncternal Therapeutics, Inc. (ONCT) EPS is -11.69 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Oncternal Therapeutics, Inc. is -0.05, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Oncternal Therapeutics, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Oncternal Therapeutics, Inc. like P/E which is -0.05, P/B which is 0.17, and PEG which is -0.01. Compare them with sector averages to evaluate if the stock is priced fairly.

Oncternal Therapeutics, Inc.

ONCT•NASDAQ

Healthcare

Biotechnology

$0.53

$-0.17(-24.12%)

Fundamental Analysis of Oncternal Therapeutics, Inc. (ONCT)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-11.69

P/E Ratio

-0.05

ROE

-1.78%

Net Margin

-20.74%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$1.56M

Shares OutstandingTotal number of shares issued

$2.96M

Book Value/ShareNet worth per share

$3.09

Revenue/ShareAnnual revenue per share

$0.56

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-11.69

Net MarginNet income as percentage of revenue

-2074.09%

Operating MarginOperating income as percentage of revenue

-2157.11%

ROEReturn on shareholders' equity

-177.58%

ROAReturn on total assets

-221.62%

ROCEReturn on capital employed

-393.08%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-9.00

Cash/ShareCash and equivalents per share

$4.92

FCF YieldFree cash flow as percentage of market cap

-1708.77%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ONCTFinancial Ratios Analysis details for ONCT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ONCTSector Benchmarking details for ONCT are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Oncternal Therapeutics, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Oncternal Therapeutics, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Oncternal Therapeutics, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Oncternal Therapeutics, Inc.

For Oncternal Therapeutics, Inc., essential financial indicators include EPS -11.69, PE -0.05, and ROE -1.78. These key ratios reveal insights into Oncternal Therapeutics, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Oncternal Therapeutics, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Oncternal Therapeutics, Inc.

Metrics like Net Margin -2074.09% and ROA -221.62% shed light on how well Oncternal Therapeutics, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Oncternal Therapeutics, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Oncternal Therapeutics, Inc.

Using ratios such as P/B Ratio 0.17 and PEG Ratio -0.01, investors can assess whether Oncternal Therapeutics, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Oncternal Therapeutics, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Oncternal Therapeutics, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.02 and Cash Flow $-9.00, provide a snapshot of Oncternal Therapeutics, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Oncternal Therapeutics, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Oncternal Therapeutics, Inc.

Investing in Oncternal Therapeutics, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Oncternal Therapeutics, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;